Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.04
ESRX's Cash to Debt is ranked lower than
97% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.73 vs. ESRX: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
ESRX' s 10-Year Cash to Debt Range
Min: 0.04  Med: 0.28 Max: No Debt
Current: 0.04
Equity to Asset 0.31
ESRX's Equity to Asset is ranked lower than
64% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.36 vs. ESRX: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
ESRX' s 10-Year Equity to Asset Range
Min: 0.11  Med: 0.33 Max: 0.6
Current: 0.31
0.11
0.6
Interest Coverage 6.18
ESRX's Interest Coverage is ranked lower than
79% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.26 vs. ESRX: 6.18 )
Ranked among companies with meaningful Interest Coverage only.
ESRX' s 10-Year Interest Coverage Range
Min: 2.78  Med: 8.55 Max: 396
Current: 6.18
2.78
396
F-Score: 7
Z-Score: 3.28
M-Score: -2.51
WACC vs ROIC
2.37%
7.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 3.79
ESRX's Operating margin (%) is ranked higher than
59% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.79 vs. ESRX: 3.79 )
Ranked among companies with meaningful Operating margin (%) only.
ESRX' s 10-Year Operating margin (%) Range
Min: 2.76  Med: 3.93 Max: 6.06
Current: 3.79
2.76
6.06
Net-margin (%) 2.15
ESRX's Net-margin (%) is ranked higher than
62% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.50 vs. ESRX: 2.15 )
Ranked among companies with meaningful Net-margin (%) only.
ESRX' s 10-Year Net-margin (%) Range
Min: -0.13  Med: 2.55 Max: 3.53
Current: 2.15
-0.13
3.53
ROE (%) 11.36
ESRX's ROE (%) is ranked higher than
59% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.50 vs. ESRX: 11.36 )
Ranked among companies with meaningful ROE (%) only.
ESRX' s 10-Year ROE (%) Range
Min: -1.3  Med: 22.76 Max: 87.47
Current: 11.36
-1.3
87.47
ROA (%) 4.15
ESRX's ROA (%) is ranked higher than
69% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.93 vs. ESRX: 4.15 )
Ranked among companies with meaningful ROA (%) only.
ESRX' s 10-Year ROA (%) Range
Min: -0.38  Med: 8.38 Max: 14.42
Current: 4.15
-0.38
14.42
ROC (Joel Greenblatt) (%) 251.80
ESRX's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 86.39 vs. ESRX: 251.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 34.51  Med: 275.03 Max: 589.99
Current: 251.8
34.51
589.99
Revenue Growth (3Y)(%) 13.30
ESRX's Revenue Growth (3Y)(%) is ranked higher than
52% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.30 vs. ESRX: 13.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 12  Med: 23.70 Max: 69.8
Current: 13.3
12
69.8
EBITDA Growth (3Y)(%) 14.90
ESRX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.60 vs. ESRX: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 3.4  Med: 25.10 Max: 87.6
Current: 14.9
3.4
87.6
EPS Growth (3Y)(%) 1.40
ESRX's EPS Growth (3Y)(%) is ranked lower than
62% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.30 vs. ESRX: 1.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 1.4  Med: 26.00 Max: 75.4
Current: 1.4
1.4
75.4
» ESRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ESRX Guru Trades in Q3 2014

Jeremy Grantham 25,535,124 sh (+39.96%)
Ray Dalio 50,162 sh (+33.22%)
First Pacific Advisors 3,441,000 sh (+21.24%)
Jim Simons 490,577 sh (+15.26%)
Vanguard Health Care Fund 3,621,200 sh (+10.91%)
Manning & Napier Advisors, Inc 3,583,120 sh (+10.64%)
David Rolfe 5,957,369 sh (+7.79%)
Charles Brandes 2,253,914 sh (+7.22%)
Diamond Hill Capital 1,657,313 sh (+6.95%)
Ruane Cunniff 5,372 sh (+6.78%)
Glenn Greenberg 4,982,726 sh (+6.50%)
Dodge & Cox 18,469,695 sh (+3.33%)
Wallace Weitz 1,776,907 sh (+1.98%)
Scott Black 129,479 sh (+0.26%)
Warren Buffett 449,489 sh (unchged)
John Keeley 30,958 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Pioneer Investments 2,704,807 sh (unchged)
Chris Davis 10,650,525 sh (-0.49%)
Jeff Auxier 75,725 sh (-2.79%)
HOTCHKIS & WILEY 1,851,500 sh (-3.48%)
Paul Tudor Jones 7,500 sh (-10.50%)
Ken Fisher 522,773 sh (-11.91%)
Mario Gabelli 247,614 sh (-32.33%)
Joel Greenblatt 48,001 sh (-78.07%)
» More
Q4 2014

ESRX Guru Trades in Q4 2014

Steven Romick 4,234,000 sh (New)
Ray Dalio 77,262 sh (+54.02%)
First Pacific Advisors 4,495,300 sh (+30.64%)
Chris Davis 13,002,699 sh (+22.09%)
Manning & Napier Advisors, Inc 4,162,823 sh (+16.18%)
David Rolfe 6,620,076 sh (+11.12%)
Dodge & Cox 19,248,979 sh (+4.22%)
Paul Tudor Jones 7,800 sh (+4.00%)
Ken Fisher 528,812 sh (+1.16%)
Diamond Hill Capital 1,673,172 sh (+0.96%)
John Keeley 30,998 sh (+0.13%)
First Eagle Investment 1,168 sh (unchged)
First Pacific Advisors 95,500 sh (unchged)
Warren Buffett Sold Out
Jeff Auxier 75,685 sh (-0.05%)
Pioneer Investments 2,667,725 sh (-1.37%)
Charles Brandes 2,207,728 sh (-2.05%)
Jeremy Grantham 24,246,330 sh (-5.05%)
Wallace Weitz 1,684,987 sh (-5.17%)
Ruane Cunniff 4,905 sh (-8.69%)
HOTCHKIS & WILEY 1,651,500 sh (-10.80%)
Scott Black 115,057 sh (-11.14%)
Vanguard Health Care Fund 3,206,500 sh (-11.45%)
Glenn Greenberg 4,088,652 sh (-17.94%)
Jim Simons 345,239 sh (-29.63%)
Mario Gabelli 134,879 sh (-45.53%)
Joel Greenblatt 25,788 sh (-46.28%)
» More
Q1 2015

ESRX Guru Trades in Q1 2015

Joel Greenblatt 493,798 sh (+1814.84%)
Paul Tudor Jones 59,441 sh (+662.06%)
Jim Simons 908,139 sh (+163.05%)
Dodge & Cox 24,221,504 sh (+25.83%)
Ray Dalio 96,962 sh (+25.50%)
HOTCHKIS & WILEY 2,003,400 sh (+21.31%)
Pioneer Investments 2,873,115 sh (+7.70%)
First Pacific Advisors 4,603,400 sh (+2.40%)
Chris Davis 13,212,411 sh (+1.61%)
Ken Fisher 534,029 sh (+0.99%)
David Rolfe 6,622,442 sh (+0.04%)
First Eagle Investment 1,168 sh (unchged)
Steven Romick 4,234,000 sh (unchged)
Ruane Cunniff 4,905 sh (unchged)
Vanguard Health Care Fund 3,206,500 sh (unchged)
Scott Black 114,807 sh (-0.22%)
John Keeley 30,458 sh (-1.74%)
Charles Brandes 2,149,660 sh (-2.63%)
Mario Gabelli 130,279 sh (-3.41%)
Diamond Hill Capital 1,593,776 sh (-4.75%)
Jeremy Grantham 21,062,316 sh (-13.13%)
Glenn Greenberg 3,495,539 sh (-14.51%)
Wallace Weitz 1,429,702 sh (-15.15%)
Manning & Napier Advisors, Inc 2,625,517 sh (-36.93%)
Jeff Auxier 27,035 sh (-64.28%)
» More
Q2 2015

ESRX Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 4,737,830 sh (+80.45%)
Steven Romick 4,234,000 sh (unchged)
Ken Fisher 533,442 sh (-0.11%)
Vanguard Health Care Fund 151,900 sh (-95.26%)
» More
» Details

Insider Trades

Latest Guru Trades with ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Express Scripts Holding Co

Steven Romick Buys 7 US and International Stocks in Q4
Steven Romick (Trades, Portfolio), a value-minded investment manager of the FPA Crescent Fund (FPACX), found just as many attractive stocks outside the U.S. as within it in the fourth quarter. Read more...
Guru Focus Value Idea Contest: Get on board the earnings train of Express Scripts (ESRX)
Express Scripts is a good company according to Warren Buffett (Trades, Portfolio). We have learned that Mr. Buffett has a knack for buying quality companies. However, a good company is not always a good stock to buy. Is it still a good investment you may be asking? Should you get on board? Let’s roll up our sleeves and do a little digging into the company’s financials and background. Read more...
Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI
According to GuruFocus' list of 52-week highs, Illinois Tool Works Inc, Express Scripts, Teva Pharmaceutical Industries Ltd, Church & Dwight Company Inc, and SunTrust Banks Inc. have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 41.50
ESRX's P/E(ttm) is ranked lower than
78% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 32.40 vs. ESRX: 41.50 )
Ranked among companies with meaningful P/E(ttm) only.
ESRX' s 10-Year P/E(ttm) Range
Min: 13.5  Med: 26.67 Max: 42.57
Current: 41.5
13.5
42.57
Forward P/E 15.04
ESRX's Forward P/E is ranked higher than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.67 vs. ESRX: 15.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 41.50
ESRX's PE(NRI) is ranked lower than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 32.40 vs. ESRX: 41.50 )
Ranked among companies with meaningful PE(NRI) only.
ESRX' s 10-Year PE(NRI) Range
Min: 13.46  Med: 26.38 Max: 42.53
Current: 41.5
13.46
42.53
P/B 4.15
ESRX's P/B is ranked lower than
78% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.62 vs. ESRX: 4.15 )
Ranked among companies with meaningful P/B only.
ESRX' s 10-Year P/B Range
Min: 1.85  Med: 7.40 Max: 31.66
Current: 4.15
1.85
31.66
P/S 0.65
ESRX's P/S is ranked lower than
57% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.56 vs. ESRX: 0.65 )
Ranked among companies with meaningful P/S only.
ESRX' s 10-Year P/S Range
Min: 0.33  Med: 0.63 Max: 1.08
Current: 0.65
0.33
1.08
PFCF 15.80
ESRX's PFCF is ranked lower than
52% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.66 vs. ESRX: 15.80 )
Ranked among companies with meaningful PFCF only.
ESRX' s 10-Year PFCF Range
Min: 8.82  Med: 14.83 Max: 25.77
Current: 15.8
8.82
25.77
POCF 14.65
ESRX's POCF is ranked lower than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.04 vs. ESRX: 14.65 )
Ranked among companies with meaningful POCF only.
ESRX' s 10-Year POCF Range
Min: 8.52  Med: 13.47 Max: 23.49
Current: 14.65
8.52
23.49
EV-to-EBIT 20.86
ESRX's EV-to-EBIT is ranked lower than
85% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.91 vs. ESRX: 20.86 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s 10-Year EV-to-EBIT Range
Min: 8.9  Med: 16.15 Max: 30.4
Current: 20.86
8.9
30.4
PEG 2.00
ESRX's PEG is ranked higher than
67% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.08 vs. ESRX: 2.00 )
Ranked among companies with meaningful PEG only.
ESRX' s 10-Year PEG Range
Min: 0.42  Med: 1.04 Max: 2.49
Current: 2
0.42
2.49
Shiller P/E 39.24
ESRX's Shiller P/E is ranked lower than
71% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.96 vs. ESRX: 39.24 )
Ranked among companies with meaningful Shiller P/E only.
ESRX' s 10-Year Shiller P/E Range
Min: 22.6  Med: 36.38 Max: 67.21
Current: 39.24
22.6
67.21
Current Ratio 0.61
ESRX's Current Ratio is ranked lower than
78% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.29 vs. ESRX: 0.61 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s 10-Year Current Ratio Range
Min: 0.57  Med: 0.90 Max: 2.21
Current: 0.61
0.57
2.21
Quick Ratio 0.50
ESRX's Quick Ratio is ranked lower than
83% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.11 vs. ESRX: 0.50 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s 10-Year Quick Ratio Range
Min: 0.47  Med: 0.80 Max: 2.15
Current: 0.5
0.47
2.15
Days Inventory 7.13
ESRX's Days Inventory is ranked lower than
54% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.72 vs. ESRX: 7.13 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s 10-Year Days Inventory Range
Min: 3.02  Med: 5.26 Max: 8.45
Current: 7.13
3.02
8.45
Days Sales Outstanding 23.14
ESRX's Days Sales Outstanding is ranked higher than
54% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 24.16 vs. ESRX: 23.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s 10-Year Days Sales Outstanding Range
Min: 13.97  Med: 28.59 Max: 78.43
Current: 23.14
13.97
78.43

Valuation & Return

vs
industry
vs
history
Price/DCF (Earnings Based) 1.29
ESRX's Price/DCF (Earnings Based) is ranked lower than
56% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.26 vs. ESRX: 1.29 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Earnings Yield (Greenblatt) (%) 4.80
ESRX's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.30 vs. ESRX: 4.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.3  Med: 6.20 Max: 11.3
Current: 4.8
3.3
11.3
Forward Rate of Return (Yacktman) (%) 22.16
ESRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 18.37 vs. ESRX: 22.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESRX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 22.2  Med: 29.70 Max: 38
Current: 22.16
22.2
38

Business Description

Industry: Health Care Plans » Health Care Plans
Compare:UNH, WLP, HUM, AET, CI » details
Traded in other countries:ESRX.Switzerland, ESRX.Mexico, 0R0W.UK, 4XS.Germany,
Express Scripts Holding Co was incorporated in the State of Delaware on July 15, 2011 as Aristotle Holding, Inc. It operates as a Pharmacy benefit management in North America. It includes HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans and government health programs. It helps health benefit providers address access and affordability concerns resulting from rising drug costs while helping to improve healthcare outcomes. It works with clients, manufacturers, pharmacists and physicians to increase efficiency in the drug distribution chain, to manage costs in the pharmacy benefit and to improve members' health outcomes and satisfaction. The Company supports healthier outcomes by applying science to health decisions. It offers solutions in four areas namely benefit choices, drug choices, pharmacy choices and health choices. Health Decision ScienceSM is the Company's approach to understand and improve the decisions that impact clinical and financial outcomes and applies principles and advanced knowledge from three disciplines: behavioral sciences, clinical specialization and actionable data. These disciplines form a powerful combination that seeks to increase the likelihood of healthier decisions and healthier outcomes. Consumerology(r), or the advanced application of the behavioral sciences to healthcare, optimizes decision mechanisms and helps make decisions easier. Therapeutic Resource CentersSM gives patients access to specialist pharmacists and nurses to close gaps in care. It has organized its operations into two business segments based on products and services offered PBM and Business Operations. The Company's PBM segment consists services such as the retail network pharmacy administration, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management, clinical solutions to improve health outcomes, such as adherence, case coordination and personalized medicine, flexible array of Medicare Part D, Medicaid and Health Insurance Marketplace offerings to support clients' benefits, specialty pharmacy, including the distribution of fertility pharmaceuticals requiring special handling or packaging, administration of a group purchasing organization and consumer health and drug information. The Business Operations segment consists of distribution of pharmaceuticals and medical supplies to providers and clinics and scientific evidence to guide the safe, effective and affordable use of medicines. The Company is subject to federal and state laws and regulations.
» More Articles for ESRX

Headlines

Articles On GuruFocus.com
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
David Rolfe Adds to Most Valuable Stakes in His Portfolio Jun 18 2015 
Dodge & Cox Keeps Buying Express Scripts May 27 2015 
Chris Davis Adds to his Express Scripts Position May 15 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
20 Questions With David Rolfe May 08 2015 
Analyzing Chris Davis' Top Holdings Apr 14 2015 
Charles Brandes' Top Growth Stocks Apr 07 2015 
CVS Health Corporation (CVS) Dividend Stock Analysis Apr 07 2015 
UnitedHealth Group Is Ready For A Huge Pharmacy Deal Apr 06 2015 

More From Other Websites
EXPRESS SCRIPTS HOLDING CO. Financials Aug 01 2015
Express Scripts excludes 20 more drugs from 2016 coverage Jul 31 2015
Express Scripts excludes 20 more drugs from 2016 coverage Jul 31 2015
How Express Scripts Makes Money Jul 29 2015
Express Scripts says costly new cholesterol drugs could 'wreak havoc' Jul 29 2015
DoD awards medical records contract to Cerner, Leidos & A... Jul 29 2015
Edited Transcript of ESRX earnings conference call or presentation 29-Jul-15 12:30pm GMT Jul 29 2015
Express Scripts (ESRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 29 2015
Dow adds 100 points as Street awaits Fed statement; earnings eyed Jul 29 2015
Express Scripts says costly new cholesterol drugs could wreak havoc Jul 29 2015
Express Scripts (ESRX) Tops Q2 Earnings, Ups 2015 View - Analyst Blog Jul 29 2015
Express Scripts Holding Co Earnings Call scheduled for 8:30 am ET today Jul 29 2015
Early movers: HLT, ANTM, ETN, TWTR, GSK & more Jul 29 2015
Express Scripts Raises Guidance as Earnings Top Views Jul 28 2015
Express Scripts tops 2Q profit forecasts Jul 28 2015
Express Scripts tops 2Q profit forecasts Jul 28 2015
Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range Jul 28 2015
Express Scripts (ESRX) Stock Gains in After-Hours Trading on Earnings Beat Jul 28 2015
EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK